SI20149B - Pharmaceutical compositions of tizoxanide and nitazoxanide - Google Patents
Pharmaceutical compositions of tizoxanide and nitazoxanide Download PDFInfo
- Publication number
- SI20149B SI20149B SI9820037A SI9820037A SI20149B SI 20149 B SI20149 B SI 20149B SI 9820037 A SI9820037 A SI 9820037A SI 9820037 A SI9820037 A SI 9820037A SI 20149 B SI20149 B SI 20149B
- Authority
- SI
- Slovenia
- Prior art keywords
- active ingredient
- composition according
- particle size
- pharmaceutical composition
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Claims (40)
- Τ ··> 1 " ' ” " " FARMACEVTSKI SESTAVKI TIZOKSANIDA IN NITAZOKSANIDA PATENTNI ZAHTEVKI 1. Farmacevtski sestavek za oralno dajanje ki vsebuje učinkovito količino učinkovine z velikostjo trdnih delcev pod 200 μίτι spojine po formuli IIpri čemer je srednja velikost navedenih delcev učinkovine nad 10 pm.
- 2. Sestavek po zahtevku 1, značilen po tem, da je srednja velikost navedenih delcev učinkovine med 10 in 100 pm.
- 3. Sestavek po zahtevku 1, značilen po tem, da je srednja velikost navedenih delcev učinkovine med 20 in 50 pm.
- 4. Sestavek po zahtevku 1, značilen po tem, da ima pod 10 mas.% navedenih delcev učinkovine velikost delcev nad 100 pm.
- 5. Sestavek po zahtevku 1, značilen po tem, da ima vsaj 50 mas.% navedenih delcev učinkovine velikost delcev pod 50 pm.
- 6. Sestavek po zahtevku 2, značilen po tem, da ima pod 10 mas.% navedenih delcev učinkovine velikost delcev pod 5 pm. 2 ο > ^ Ο -» ο 2 ο > ^ Ο -» ο Λ ·> Τ ·..> Λ·»-) > » ι > :» ι ·> > ) )
- 7. Sestavek po zahtevku 1, značilen po tem, da obsega navedeni sestavek nadalje vsaj še eno farmacevtsko sprejemljivo kislino.
- 8. Sestavek po zahtevku 7, značilen po tem, da je navedena farmacevtsko sprejemljiva kislina izbrana iz skupine, ki obsega citronsko, glutaminsko, jantarno, etansulfonsko, ocetno, vinsko, askorbinsko, metansulfonsko, fumarno, adipinsko, jabolčno kislino ter njihove zmesi.
- 9. Sestavek po zahtevku 7, značilen po tem, da je navedena učinkovina v obliki trdnih delcev z velikostjo delcev pod 200 pm in srednjo velikost delcev nad 10 pm, in da je razmerje med maso farmacevtsko sprejemljive kisline/maso navedenih trdnih delcev med 0.01 in 0.5.
- 10. Sestavek po zahtevku 9, značilen po tem, da je razmerje med maso farmacevtsko sprejemljive kisline/maso navedenih trdnih delcev učinkovine med 0.03 in 0.2.
- 11. Uporaba farmacevtskega sestavka, ki vsebuje kot učinkovino najmanj eno spojino, izbrano iz skupine, ki obstaja iz spojine s formulo (I)in spojine s formulo (II) N O - CO - CH N02 S Λ NH—CO7 V (II) 3 3 Ο ,1 «ϊ ^ Ο > τ > -> “> ·;1 t οο ίο η η ^ mi Ο ,* ) 9 '> ) > -» 9 ι > Ί > Λ ·Ί > -J 1 ·) *> ' ' ·> Τ ,11 za pripravo zdravila za zdravljenje imunsko prizadetega sesalca okuženega z mikroorganizmom, izbranim iz skupine, ki obstaja iz Cryptosporidium parvum, Isospora belli, Enterocytzoon bieneusi, Encephalitozoon intestinalis, Mycobacterium tuberculosis, Mycobacterium avium intracellulare, Pneumocystis carinil in Toxoplasma gondii.
- 12. Uporaba farmacevtskega sestavka po zahtevku 11, značilna po tem, da je navedena učinkovina v obliki delcev s srednjo velikostjo delcev med 10 in 200 pm.
- 13. Uporaba farmacevtskega sestavka po zahtevku 11, značilna po tem, da navedena učinkovina v obliki delcev s srednjo velikostjo delcev med 20 in 50 pm.
- 14. Uporaba farmacevtskega sestavka po zahtevku 11, značilna po tem, da obsega navedeni farmacevtski sestavek nadalje vsaj še eno farmacevtsko sprejemljivo kislino.
- 15. Uporaba farmacevtskega sestavka po zahtevku 14, značilna po tem, da je navedena farmacevtsko sprejemljiva kislina izbrana iz skupine, ki obsega citronsko, glutaminsko, jantarno, etansulfonsko, ocetno, vinsko, askorbinsko, metansulfonsko, fumarno, adipinsko, jabolčno kislino ter njihove zmesi.
- 16. Uporaba farmacevtskega sestavka po zahtevku 11, značilna po tem, da je navedena učinkovina spojina s formulo (I).
- 17. Uporaba farmacevtskega sestavka po zahtevku 11, značilna po tem, da je navedena učinkovina spojina s formulo (II).
- 18. Uporaba farmacevtskega sestavka po zahtevku 11, značilna po tem, da je navedeni sesalec človek in je navedena učinkovina aplicirana v množini od 500 do 2000 mg dnevno. 4 3 Ο on-* ο j ο ο ί> ο ο ο ο ο ο ο η > η η η η ο η ο η "* * θ'*) > -> ·*
- 19. Uporaba farmacevtskega sestavka po zahtevku 18, značilna po tem, da je navedena učinkovina aplicirana v množini od 1000 do 1500 mg dnevno.
- 20. Uporaba farmacevtskega sestavka, ki vsebuje kot učinkovino najmanj eno spojino, izbrano iz skupine, ki obstaja iz spojine s formulo (I)in spojine s formulo (II) O - CO - CH n-,N v 3 NH—CONO, A (ID za pripravo zdravila za zdravljenje parazitske okužbe s trematodo, izbrano iz skupine, ki obstaja iz Schistosoma, Fasciola, Fasciolopsis, Dicrocoelium, Heterophyes in Metagonimus.
- 21. Uporaba farmacevtskega sestavka, ki vsebuje kot učinkovino najmanj eno spojino, izbrano iz skupine, ki obstaja iz spojine s formulo (I) NONH— CO(I) o O 10 11 .·> -> > -·» > -v ' ''>> > ) » ' O .) > -> ί Λ » -.1 in spojine s formulo (II) N Λ O - CO - CH no2 S nh—co(II) za pripravo zdravila za zdravljenje parazitske okužbe s trematodo, izbrano iz skupine, ki obstaja iz Schistosoma mansoni, Schistosoma haematobium, Schistosoma mekongi, Schistosoma japonicum, Schistosoma intercalatum; Fasciola hepatica, Fasciola gigantica, Fasciolopsis biski, Dicrocoelium dendriticum, Heterophyes hetemphyes in Metagonimus yokogawa.
- 22. Uporaba farmacevtskega sestavka po zahtevku 21, značilna po tem, da je navedena učinkovina v obliki delcev s srednjo velikostjo delcev med 10 in 200 μιτι.
- 23. Uporaba farmacevtskega sestavka po zahtevku 22, značilna po tem, da je navedena učinkovina v obliki delcev s srednjo velikostjo delcev med 20 in 50 pm.
- 24. Uporaba farmacevtskega sestavka po zahtevku 21, značilna po tem, da obsega navedeni farmacevtski sestavek nadalje vsaj še eno farmacevtsko sprejemljivo kislino.
- 25. Uporaba farmacevtskega sestavka po zahtevku 24, značilna po tem, da je navedena farmacevtsko sprejemljiva kislina izbrana iz skupine, ki obsega citronsko, glutaminsko, jantarno, etansulfonsko, ocetno, vinsko, askorbinsko, metansulfonsko, fumarno, adipinsko, jabolčno kislino ter njihove zmesi. 6 » ·>ο ^ 3 Λ "> -> D ·Ί 6 » ·>ο ^ 3 Λ "> -> D ·Ί Ο > Λ
- 26. Uporaba farmacevtskega sestavka po zahtevku 24, značilna po tem, da je razmerje med maso farmacevtsko sprejemljive kisline/maso navedenih delcev učinkovine med 0.01 in 0.5.
- 27. Uporaba farmacevtskega sestavka po zahtevku 21, značilna po tem, da je navedena učinkovina spojina s formulo (I).
- 28. Uporaba farmacevtskega sestavka po zahtevku 21, značilna po tem, da je navedena učinkovina spojina s formulo (II).
- 29. Farmacevtska pasta za zunanjo aplikacijo, značilna po tem, da navedena pasta vsebuje učinkovito količino učinkovine z velikostjo trdnih delcev pod 200 μηι spojine po formuli IIpri čemer imajo navedeni delci velikost pod 200 μιτι in srednjo velikost delcev nad 10 μιτι ; - najmanj eno omakalo; - najmanj en dodatek izbran iz skupine iz skupine, ki obstaja iz cetil alkohola, gliceridnih derivatov, propilen glikola in njihovih zmesi; - najmanj eno zgoščevalo.
- 30. Farmacevtski sestavek za oralno aplikacijo ki vsebuje učinkovito količino učinkovine z velikostjo trdnih delcev pod 200 μιτι spojine po formuli IIpri čemer je srednja velikost navedenih delcev učinkovine nad 10 pm; in - najmanj eno granulirno sredstvo.
- 31. Sestavek po zahtevku 30, značilen po tem, da je navedeno granulirno sredstvo izbrano iz skupine, ki obstaja iz polivinilpirolidona, vode, alkohola, saharoze, hidroksil celuloze, in njihovih zmesi.
- 32. Sestavek po zahtevku 30, značilen po tem, da obsegajo navedeni granulirani delci trdne učinkovine vsaj še eno farmacevtsko sprejemljivo kislino.
- 33. Sestavek po zahtevku 31, značilen po tem, da je navedena farmacevtsko sprejemljiva kislina izbrana iz skupine, ki obsega citronsko, glutaminsko, jantarno, etansulfonsko, ocetno, vinsko, askorbinsko, metansulfonsko, fumarno, adipinsko, jabolčno kislino ter njihove zmesi.
- 34. Sestavek po zahtevku 32, značilen po tem, da je razmerje med maso farmacevtsko sprejemljive kisline/maso navedene učinkovine med 0.01 in 0.5.
- 35. Dozirna oblika za oralno aplikacijo ki vsebuje učinkovito količino učinkovine z velikostjo trdnih delcev pod 200 pm spojine po formuli II NONH—co O - CO - CH * 3 '/ v (II) 8 > 'i > > O 1 » o >rt 1 Λ pri čemer je srednja velikost navedenih delcev učinkovine nad 10 μΐη; - najmanj eno omakalno sredstvo; in - najmanj en škrobni derivat.
- 36. Dozirna oblika po zahtevku 35, značilen po tem, da nadalje obsega vsaj še eno farmacevtsko sprejemljivo kislino.
- 37. Dozirna oblika po zahtevku 35, značilen po tem, da so navedeni delci učinkovine granulirani v prisotnosti granulirnega sredstva, ki vsebuje od 2 do 99.97 mas.% navedene učinkovine in od 0.03 do 10 mas.% granulirnega sredstva.
- 38. Dozirna oblika po zahtevku 37, značilen po tem, da je navedeno granulirno sredstvo izbrano iz skupine, ki obstaja iz polivinilpirolidona, vode, alkohola, saharoze, hidroksil celuloze, in njihovih zmesi.
- 39. Vodna ali drugačna tekoča suspenzija delcev za oralno aplikacijo ki vsebuje učinkovito količino učinkovine z velikostjo trdnih delcev pod 200 μιη spojine po formuli II(II) pri čemer je srednja velikost navedenih delcev učinkovine nad 10 pm; in najmanj ene farmacevtsko sprejemljive kisline, pri čemer je pH suspenzije med 2 in 6. o n rto !»β ί9βΟ 3 Ί O ·> O "> O O > -> Ί ·> ·> "> > O > θ’» ·1 1 » '.! » 1 > > > 1 1 -> > -> Ί > -Ί ^ 1 ) 9
- 40. Suspenzija po zahtevku 39, značilna po tem, da nadalje obsega granulirno sredstvo.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/852,447 US5968961A (en) | 1997-05-07 | 1997-05-07 | Pharmaceutical compositions of tizoxanide and nitazoxanide |
US08/887,809 US5965590A (en) | 1994-09-08 | 1997-07-03 | Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide |
US08/887,810 US5856348A (en) | 1994-09-08 | 1997-07-03 | Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide |
PCT/US1998/009229 WO1998050035A1 (en) | 1997-05-07 | 1998-05-06 | Pharmaceutical compositions of tizoxanide and nitazoxanide |
Publications (2)
Publication Number | Publication Date |
---|---|
SI20149A SI20149A (sl) | 2000-08-31 |
SI20149B true SI20149B (en) | 2001-08-31 |
Family
ID=27420362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI9820037A SI20149B (en) | 1997-05-07 | 1998-05-06 | Pharmaceutical compositions of tizoxanide and nitazoxanide |
Country Status (35)
Country | Link |
---|---|
EP (2) | EP1222921B1 (sl) |
JP (1) | JP3739802B2 (sl) |
KR (2) | KR100426657B1 (sl) |
CN (2) | CN1158074C (sl) |
AP (1) | AP1103A (sl) |
AR (1) | AR057242A2 (sl) |
AT (2) | ATE281166T1 (sl) |
AU (1) | AU740022B2 (sl) |
BG (2) | BG109365A (sl) |
BR (1) | BR9808722A (sl) |
CA (2) | CA2418634C (sl) |
CZ (2) | CZ298269B6 (sl) |
DE (2) | DE69827417T2 (sl) |
DK (2) | DK1222921T3 (sl) |
EA (2) | EA002920B1 (sl) |
EE (1) | EE04870B1 (sl) |
ES (2) | ES2232687T3 (sl) |
GE (1) | GEP20032970B (sl) |
HK (1) | HK1025907A1 (sl) |
HU (1) | HU229641B1 (sl) |
IL (2) | IL155799A (sl) |
IS (1) | IS2087B (sl) |
LV (1) | LV12492B (sl) |
ME (1) | ME00530B (sl) |
NO (2) | NO313983B1 (sl) |
NZ (2) | NZ500149A (sl) |
OA (1) | OA11169A (sl) |
PL (1) | PL193275B1 (sl) |
PT (2) | PT1222921E (sl) |
RO (1) | RO120605B1 (sl) |
SI (1) | SI20149B (sl) |
SK (2) | SK283947B6 (sl) |
TR (1) | TR199902733T2 (sl) |
UA (2) | UA57079C2 (sl) |
WO (1) | WO1998050035A1 (sl) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2467321A1 (en) | 2004-05-14 | 2005-11-14 | Paul J. Santerre | Polymeric coupling agents and pharmaceutically-active polymers made therefrom |
CA2636527C (en) | 2006-01-09 | 2016-05-17 | Romark Laboratories, L.C. | Viral hepatitis treatment |
PL2395840T3 (pl) * | 2009-02-13 | 2020-09-07 | Romark Laboratories, L.C. | Preparaty farmaceutyczne nitazoksanidu o kontrolowanym uwalnianiu |
PE20121118A1 (es) | 2009-05-12 | 2012-09-05 | Romark Lab Lc | Compuestos de haloalquil heteroaril benzamida |
EP2445349B1 (en) | 2009-06-26 | 2022-02-09 | Romark Laboratories, L.C. | Compounds and methods for treating influenza |
US9498441B2 (en) | 2012-01-27 | 2016-11-22 | Siegfried Rhein S.A. De C.V. | Nitazoxadine composition and process to prepare same |
AU2015346413B2 (en) * | 2014-11-11 | 2019-08-29 | Romark Laboratories, L.C. | Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof |
US11612567B2 (en) | 2018-02-02 | 2023-03-28 | Ripple Therapeutics Corporation | Ocular inserts comprising a covalently linked steroid dimer |
EP4146664A2 (en) | 2020-05-01 | 2023-03-15 | Ripple Therapeutics Corporation | Heterodimer compositions and methods for the treatment of ocular disorders |
WO2022130406A1 (en) * | 2020-12-15 | 2022-06-23 | Cipla Limited | Inhalation composition of nitazoxanide or its derivatives for use in coronavirus disease |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1437800A (en) * | 1973-08-08 | 1976-06-03 | Phavic Sprl | Derivatives of 2-benzamido-5-nitro-thiazoles |
US4315018A (en) * | 1978-12-07 | 1982-02-09 | Rossignol Jean F | Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives |
US5387598A (en) * | 1994-04-13 | 1995-02-07 | Rossignol; Jean-Francois | Composition and galenic formulation suitable for combatting affections of the lower abdomen |
US5578621A (en) * | 1994-09-08 | 1996-11-26 | Romark Lab Lc | Benzamide derivatives |
-
1998
- 1998-05-06 HU HU0003330A patent/HU229641B1/hu not_active IP Right Cessation
- 1998-05-06 CZ CZ0391199A patent/CZ298269B6/cs not_active IP Right Cessation
- 1998-05-06 EP EP02002887A patent/EP1222921B1/en not_active Expired - Lifetime
- 1998-05-06 ME MEP-2008-877A patent/ME00530B/me unknown
- 1998-05-06 CN CNB988049007A patent/CN1158074C/zh not_active Expired - Fee Related
- 1998-05-06 AP APAP/P/1999/001675A patent/AP1103A/en active
- 1998-05-06 EA EA200100956A patent/EA002920B1/ru not_active IP Right Cessation
- 1998-05-06 TR TR1999/02733T patent/TR199902733T2/xx unknown
- 1998-05-06 CA CA002418634A patent/CA2418634C/en not_active Expired - Fee Related
- 1998-05-06 KR KR10-1999-7009930A patent/KR100426657B1/ko not_active IP Right Cessation
- 1998-05-06 NZ NZ500149A patent/NZ500149A/en not_active IP Right Cessation
- 1998-05-06 DK DK02002887T patent/DK1222921T3/da active
- 1998-05-06 DE DE69827417T patent/DE69827417T2/de not_active Expired - Lifetime
- 1998-05-06 EE EEP199900578A patent/EE04870B1/xx unknown
- 1998-05-06 GE GEAP19985109A patent/GEP20032970B/en unknown
- 1998-05-06 PT PT02002887T patent/PT1222921E/pt unknown
- 1998-05-06 ES ES02002887T patent/ES2232687T3/es not_active Expired - Lifetime
- 1998-05-06 AT AT02002887T patent/ATE281166T1/de active
- 1998-05-06 IL IL15579998A patent/IL155799A/en not_active IP Right Cessation
- 1998-05-06 SK SK708-2003A patent/SK283947B6/sk unknown
- 1998-05-06 SI SI9820037A patent/SI20149B/sl not_active IP Right Cessation
- 1998-05-06 CZ CZ20060366A patent/CZ298270B6/cs not_active IP Right Cessation
- 1998-05-06 PL PL336805A patent/PL193275B1/pl not_active IP Right Cessation
- 1998-05-06 IL IL13251698A patent/IL132516A/xx not_active IP Right Cessation
- 1998-05-06 DE DE69809928T patent/DE69809928T2/de not_active Expired - Lifetime
- 1998-05-06 NZ NZ513881A patent/NZ513881A/xx not_active IP Right Cessation
- 1998-05-06 CA CA002288003A patent/CA2288003C/en not_active Expired - Fee Related
- 1998-05-06 DK DK98920285T patent/DK1005342T3/da active
- 1998-05-06 EP EP98920285A patent/EP1005342B1/en not_active Expired - Lifetime
- 1998-05-06 WO PCT/US1998/009229 patent/WO1998050035A1/en active IP Right Grant
- 1998-05-06 ES ES98920285T patent/ES2150404T3/es not_active Expired - Lifetime
- 1998-05-06 SK SK1511-99A patent/SK283946B6/sk unknown
- 1998-05-06 RO RO99-01166A patent/RO120605B1/ro unknown
- 1998-05-06 AU AU72895/98A patent/AU740022B2/en not_active Ceased
- 1998-05-06 JP JP54843798A patent/JP3739802B2/ja not_active Expired - Fee Related
- 1998-05-06 EA EA199901012A patent/EA002908B1/ru not_active IP Right Cessation
- 1998-05-06 CN CNB2004100459536A patent/CN100515420C/zh not_active Expired - Fee Related
- 1998-05-06 PT PT98920285T patent/PT1005342E/pt unknown
- 1998-05-06 AT AT98920285T patent/ATE228839T1/de active
- 1998-05-06 BR BR9808722-3A patent/BR9808722A/pt not_active IP Right Cessation
- 1998-05-06 KR KR1020037011334A patent/KR100576646B1/ko not_active IP Right Cessation
- 1998-06-05 UA UA99126626A patent/UA57079C2/uk unknown
- 1998-12-06 BG BG109365A patent/BG109365A/en unknown
-
1999
- 1999-10-19 IS IS5223A patent/IS2087B/is unknown
- 1999-10-29 OA OA9900239A patent/OA11169A/en unknown
- 1999-11-04 NO NO19995406A patent/NO313983B1/no not_active IP Right Cessation
- 1999-12-01 LV LVP-99-170A patent/LV12492B/en unknown
- 1999-12-06 BG BG103958A patent/BG64973B1/bg unknown
-
2000
- 2000-08-17 HK HK00105181A patent/HK1025907A1/xx not_active IP Right Cessation
-
2002
- 2002-04-18 NO NO20021832A patent/NO335781B1/no not_active IP Right Cessation
-
2003
- 2003-04-04 UA UA2003042974A patent/UA74388C2/uk unknown
-
2006
- 2006-12-14 AR ARP060105534A patent/AR057242A2/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4665081A (en) | Solid nifedipine preparations and a process for preparing same | |
EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
EP2709592B1 (en) | Pharmaceutical composition of rosuvastatin calcium | |
SI20149B (en) | Pharmaceutical compositions of tizoxanide and nitazoxanide | |
HUT75150A (en) | Controlled release pharmaceutical compositions based on salts of gamma hydroxy-butyric acid | |
JP2007091633A (ja) | メキタジン、イブプロフェン及びトラネキサム酸含有医薬組成物 | |
AU2006245564A1 (en) | Pharmaceutical formulation of apomorphine for buccal administration | |
SK281441B6 (sk) | Použitie 2-amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzotiazolu | |
AU776912B2 (en) | Directly compressible matrix for controlled release of single daily doses of clarithromycin | |
SK4032000A3 (en) | MEDICAMENT FORMULATION WITH A CONTROLLED RELEASE OF AN ACTIVEì (54) AGENT | |
DE60042168D1 (de) | Chronotherapeutische diltiazem formulierungen und deren verabreichung | |
EP1365751A2 (fr) | Granules et granules enrobes au gout masque | |
WO2004028567A1 (ja) | 薬物吸収性改善剤 | |
NL8900734A (nl) | Vaste, snel uiteenvallende toedieningsvormen. | |
ES2648338T3 (es) | Composiciones farmacéuticas de raltegravir, procedimientos para su preparación para su uso | |
AU623731B2 (en) | Water dispersible gemfibrozil compositions | |
BG65472B1 (bg) | Използване на саредутант и неговите фармацевтичноприемливи соли за приготвяне на лекарствено средство за използване за лечение или профилактика на голямо депресивно разтройство | |
JP2003171313A (ja) | 医薬組成物 | |
DE60035579D1 (de) | Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme | |
DK1255535T3 (da) | Lægemiddelsammensætning med kontrolleret frisætning indeholdende tramadol-hydrochlorid | |
US20020037899A1 (en) | Compositions containing an inhibitor of dihydrofolate reductase and a folate | |
CA3183290A1 (en) | Tablet comprising opicapone | |
EP0522006A1 (en) | Compositions comprising cytotoxic agent and permeation enhancers | |
WO1999066929A1 (en) | Compositions and methods for treating elevated blood cholesterol | |
CA1329764C (en) | Pharmaceutical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
IF | Valid on the event date | ||
KO00 | Lapse of patent |
Effective date: 20130108 |